News

Updates from BCI

BCIlanyard

Navigate via the main menu, post Categories to the right or Tags below. Join the discussion!

New trial using combination therapy extends survival in triple-negative breast cancer

Posted in General News, BCI on the Road, Publications Published by Bethan Warman 22 October 2018

New trial using combination therapy extends survival in triple-negative breast cancer

New research led by Barts Cancer Institute and St Bartholomew’s Hospital has provided new hope for people with an aggressive type of breast cancer. The phase 3 clinical trial has shown that by using a combination of immunotherapy and chemotherapy, the body’s own immune system can be tuned to attack triple-negative breast cancer, extending survival by up to ten months.

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Posted in General News, Publications Published by Bethan Warman 17 October 2018

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC). The phase 1 clinical trial, led by Prof Peter Schmid, Centre Lead for BCI’s Centre for Experimental Cancer Medicine, is the first to report the long-term safety and efficacy of the drug for mTNBC, and may represent significant steps forward for treatment of this disease.

Accelerator Award to improve early detection and intervention of blood cancers

Posted in General News, Grants & Awards Published by Bethan Warman 09 October 2018

Accelerator Award to improve early detection and intervention of blood cancers

BCI researchers are lead members of an international team to be funded by an Accelerator Award, which will bring together scientists from the UK, Spain and Italy in a bid to improve early detection and intervention of blood cancers. The award of £4.8M over 5 years, funded through a partnership between Cancer Research UK (CRUK), AIRC and FC AECC, encourages cross-institutional collaboration to unite resources and expertise to accelerate progress in cancer research.

Blood Cancer Awareness Month 2018

Posted in General News Published by Bethan Warman 28 September 2018

Blood Cancer Awareness Month 2018

Blood Cancer Awareness Month takes place every September to raise awareness of the challenges faced by those living with blood cancer. In the UK, blood cancer is the fifth most common cancer, with 240,000 people living with the disease and 38,000 people being diagnosed with a type of blood cancer each year. The three main blood cancer types are leukaemia, lymphoma and myeloma; however, there are over 100 individual types.

World Cancer Research Day 2018

Posted in General News Published by Bethan Warman 24 September 2018

World Cancer Research Day 2018

Today is World Cancer Research Day- a day dedicated to raising awareness of the importance of cancer research. Thanks to a united effort by researchers from around the world, cancer survival rates have doubled in the last 40 years, and 50% of those diagnosed with cancer now survive. To continue to improve these statistics, it is vital to identify new and more effective early detection methods and treatments that can improve the lives of those with cancer.

BCC key partner in new £14m CRUK City of London Centre

Posted in General News, BCI Spotlight Articles Published by Bethan Warman 17 September 2018

BCC key partner in new £14m CRUK City of London Centre

We are delighted to announce that researchers from the BCC will play a leading role in the new Cancer Biotherapeutics Hub launched by CRUK - ‘The CRUK City of London Centre’. The new centre will bring together world-leading cancer researchers from across London - BCC, UCL, KCL and the Francis Crick Institute.

Study links widely-used drug azathioprine to skin cancers

Posted in General News, Publications Published by Bethan Warman 14 September 2018

Study links widely-used drug azathioprine to skin cancers

A drug used to treat inflammatory bowel disease and arthritis, and prevent organ rejection in transplant patients, has been identified as an important contributor to skin cancer development in a study by researchers from Queen Mary University of London, including our Barts Cancer Research UK Centre (BCC) Bioinformatics team, the University of Dundee and the Wellcome Sanger Institute.

VOICE 2018: From bedside to bench

Posted in General News, Engagement Published by Bethan Warman 12 September 2018

VOICE 2018: From bedside to bench

Last week, BCI held the 2018 VOICE (Vision On Information, Confidence & Engagement) course- a study week that aims to take patient advocates from bedside to bench by providing an introduction to basic cancer biology, research terminology and study design. This unique course was developed by Independent Cancer Patients’ Voice (ICPV)- a patient advocate group led by patients for patients- to empower patient advocates and increase their confidence to get involved in the cancer conversation.

‘Chromosomal Catastrophes’ in Colorectal Cancer

Posted in General News, Publications Published by Bethan Warman 05 September 2018

‘Chromosomal Catastrophes’ in Colorectal Cancer

Understanding how cancers develop and change over time is a big challenge. For obvious reasons, scientists can’t simply sit and watch a cancer growing in a person. Members of the Evolution and Cancer Laboratory at the BCI, including lead author Dr William Cross, were part of a collaborative team that set out to identify when particular genetic changes arise during bowel cancer development. Their findings, published in Nature Ecology & Evolution, indicated that ‘chromosomal catastrophes’ sometimes occur along the evolutionary timeline of colorectal cancer development.

SNPnexus: Assessing the impact of genetic variation

Posted in General News, Publications Published by Bethan Warman 30 August 2018

SNPnexus: Assessing the impact of genetic variation

A team of researchers from BCI’s Centre for Molecular Oncology, led by Prof Claude Chelala, have made new developments to SNPnexus- a computational tool that allows for the assessment of the functional effect of sequence variants within the genome. The team hope that the new release will facilitate the development of precision medicine, allowing for the identification of effective gene targets for therapy.

[12 3 4 5  >>  
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.